In order to rule out that additive effects of Cox-2 inhibition and anti-angiogenic therapy only occur in a single breast cancer model and might therefore not be representative we treated 66cl4 tumor-bearing mice with ASA and sunitinib. Here, PTGS2 is linked to breast cancer.